Gonadotropin secretion in rats bearing a prolactin-secreting pituitary tumor: effects of naloxone administration

Opioid control of luteinizing hormone secretion in humans

The observation that heroin-addicted subjects are amenorrheic and/or hypogonadic suggested a possible role of endogenous opioid peptides (EOP) in the regulation of the hypothalamus-pituitary-gonodal axis. Because EOP are localized all through the axis, they may influence the reproductive function acting at various levels. The injection of morphine decreases plasma LH levels, abolishing the pulsatile pattern of secretion. The evidence that naloxone, an opiate receptor blockade, increases LH levels suggests a tonic inhibitory action of EOP. The naloxone-induced LH increase is not observed before pubertal maturation, in both sexes, and is absent in children with delayed or precocious puberty and in those with Klinefelter's or Turner's syndrome, suggesting a role of gonadal function on the opioid control of LH secretion. In adult women this LH response to naloxone is present during the periovulatory and the luteal phase of the menstrual cycle, suggesting a permissive role of estradiol and mainly of progesterone on the action of EOP on the LH secretion. Indeed, in amenorrheic subjects naloxone lacks to stimulate plasma LH levels and the treatment for the induction of ovulation restores this activity. An increased inhibitory action of EOP on GnRH release may explain the inefficacy of naloxone to stimulate LH secretion in hypogonadotropinic patients, while a decreased action has been hypothesized in postmenopausal women. The clinical implications of EOP in reproductive medicine appear to be promising.

Hyperprolactinemia and estrogen-induced rhythms in LH and prolactin release in the ovariectomized rat

Short-term (9 days) hyperprolactinemia induced by pituitary grafts reduced basal plasma LH levels in ovariectomized rats whereas long-term (31 days) grafts increased basal LH levels. Although long-term grafts inhibited estradiol-induced prolactin surges, hyperprolactinemia had no effect on the LH surge. It is concluded that the estrogen-treated ovariectomized rat is not suitable for studying the effects of hyperprolactinemia on LH release.

Impairment of opioid control of luteinizing hormone secretion in menstrual disorders

With the aim of examining central opioid influences on the control of luteinizing hormone (LH) secretion, we evaluated the LH response to naloxone, an opioid receptor antagonist, in patients affected by normo-, hyper-, and hypogonadotropic amenorrhea, polycystic ovarian disease and hyperprolactinemia. The results indicate that opioid influences are altered in well-defined pathologic conditions (hyperprolactinemia, obesity), in addition to being modified by gonadal steroids.

Effects of bromocriptine on pituitary-testicular function in the rat: possible inhibition of in vitro production of androgen by Leydig cells

The effect of bromocriptine (BR) on pituitary-testicular function has been investigated in vivo and in vitro in adult male rats. Testosterone production in vitro by collagenase- dispersed Leydig cells from 84-day-old rats was evaluated in the presence and absence of hCG and/or different doses of BR. In the presence of 1.5 X 10(-5) M BR, both basal and hCG-stimulated testosterone production were decreased whereas at lower doses BR was ineffective. In vivo 60-day-old rats were injected sc with BR (150 micrograms/rat or 750 micrograms/rat twice daily) or vehicle for 24 days. This treatment reduced the plasma level and pituitary content of prolactin, slightly increased the plasma levels of LH and FSH but did not affect pituitary gonadotrophin content. Irrespective of the dose of BR injected, plasma levels of androgen did not change, but with the large dose of BR a decrease in testicular content of testosterone (P = 0.05) was observed. In the same animals the number of LH/hCG receptors was significantly reduced, and the sensitivity of the isolated Leydig cells to hCG stimulation in vitro was reduced; however, both the basal secretion and the maximum testosterone response to hCG were unaffected. These results show impairment of pituitary-testicular function in BR-treated rats, either as a result of BR-induced hypoprolactinaemia or as a consequence of direct effects of BR on the Leydig cells.

Endogenous opiates: 1981

This paper is the fourth of an annual series reviewing the research concerning the endogenous opiate peptides. This installment covers only work published during 1981 and attempts to provide a comprehensive, but not exhaustive, survey of the area. Previous papers in the series have dealt with research done before 1981. Topics concerning endogenous opiates reviewed here include a delineation of their receptors, their distribution, their precursors and degradation, behavioral effects resulting from their administration, their possible involvement in physiological responses, and their interactions with other peptides and hormones. Due to the burgeoning literature in this field, the comprehensive nature of this review in the future will be limited to considerations of behavioral phenomena related to the endogenous opiates.